Quest PharmaTech Inc.

TSXV:QPT Stock Report

Market Cap: CA$5.9m

Quest PharmaTech Management

Management criteria checks 3/4

Quest PharmaTech's CEO is Madi Madiyalakan, appointed in Aug 2006, has a tenure of 19.5 years. total yearly compensation is CA$287.50K, comprised of 87% salary and 13% bonuses, including company stock and options. directly owns 1.89% of the company’s shares, worth CA$112.00K. The average tenure of the management team and the board of directors is 21.2 years and 4.6 years respectively.

Key information

Madi Madiyalakan

Chief executive officer

CA$287.5k

Total compensation

CEO salary percentage86.96%
CEO tenure19.5yrs
CEO ownership1.9%
Management average tenure21.2yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Madi Madiyalakan's remuneration changed compared to Quest PharmaTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Oct 31 2025n/an/a

-CA$97k

Jul 31 2025n/an/a

-CA$1m

Apr 30 2025n/an/a

-CA$245k

Jan 31 2025CA$288kCA$250k

-CA$2m

Oct 31 2024n/an/a

-CA$2m

Jul 31 2024n/an/a

-CA$3m

Apr 30 2024n/an/a

-CA$4m

Jan 31 2024CA$390kCA$250k

-CA$3m

Oct 31 2023n/an/a

-CA$63m

Jul 31 2023n/an/a

-CA$64m

Apr 30 2023n/an/a

-CA$64m

Jan 31 2023CA$269kCA$215k

-CA$65m

Oct 31 2022n/an/a

-CA$78m

Jul 31 2022n/an/a

-CA$87m

Apr 30 2022n/an/a

-CA$86m

Jan 31 2022CA$189kCA$40k

-CA$85m

Oct 31 2021n/an/a

CA$68m

Jul 31 2021n/an/a

CA$81m

Apr 30 2021n/an/a

CA$83m

Jan 31 2021CA$270kCA$40k

CA$190m

Compensation vs Market: Madi's total compensation ($USD210.27K) is above average for companies of similar size in the Canadian market ($USD158.75K).

Compensation vs Earnings: Madi's compensation has been consistent with company performance over the past year.


CEO

Madi Madiyalakan

19.5yrs
Tenure
CA$287,500
Compensation

Dr. Ragupathy Madiyalakan, Ph D., also known as Madi, serves as Chief Executive Officer at OncoQuest Inc. He has been the Chief Executive Officer of Quest PharmaTech, Inc. since August 2006. Dr. Madiyalaka...


Leadership Team

NamePositionTenureCompensationOwnership
Ragupathy Madiyalakan
CEO & Director19.5yrsCA$287.50k1.89%
CA$ 112.0k
Pierre Vermette
Chief Financial Officer21.1yrsCA$40.39k1.08%
CA$ 64.1k
Roger Andrews
Head of Investor Relations & Corporate Communications21.3yrsno datano data
Douglas Bachman
Vice President of Corporate Developmentno dataCA$37.94kno data
Thomas Woo
Vice President of Product Development23.7yrsCA$15.00kno data
21.2yrs
Average Tenure

Experienced Management: QPT's management team is seasoned and experienced (21.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ragupathy Madiyalakan
CEO & Director21.7yrsCA$287.50k1.89%
CA$ 112.0k
John Lievonen
Independent Chairman4.6yrsCA$13.00kno data
Jeffrey Shon
Independent Director4.6yrsCA$13.00k0.21%
CA$ 12.2k
Bradley Glass
Independent Director1.8yrsCA$3.00kno data
4.6yrs
Average Tenure

Experienced Board: QPT's board of directors are considered experienced (4.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/03 02:53
End of Day Share Price 2026/01/30 00:00
Earnings2025/10/31
Annual Earnings2025/01/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quest PharmaTech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.